Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Struggling to find time for money-making? Here are ways to fit income opportunities into your busy schedule seamlessly.
27,638 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Lumentum’s March 23 S&P 500 inclusion has sparked renewed buying and a broader market debate about how far the rally ...
AI chip demand is reshaping tech markets, and Taiwan Semiconductor Manufacturing sits at the center. This article exp...
Fastenal is delivering steady, long‑term gains through an embedded, service‑driven model. Here’s why the stock fits a...
Investors noticed a meaningful rebound in Jumia’s growth metrics, nudging the stock higher. This article breaks down ...
Investors are watching Crinetics' Q1 2026 results for clues on milestones, cash runway, and partnerships. This guide ...
Bank Of America boosts its Affirm Holdings target to $88 after a solid quarter, framing May 12 investor day as a cata...
A rising iPhone upgrade cycle is quietly lifting a little-known stock. This article breaks down why the move makes it...
Flyhomes has weathered a boom-bust housing cycle by recalibrating its business and embracing profitability over rapid...
XRP’s bullish signals building as ETF inflows surge and on-chain activity strengthens, yet the token’s price remains ...
Grab is moving to pilot a new delivery robot in Singapore’s Punggol district by late 2026, aiming to relieve labor sh...
SpaceX stands at a pivotal crossroads as the Starship launch window tightens. Investors are weighing how a successful...